Kuvatris Therapeutics, Inc.
PXMDDelisted Aug 8, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811623
Kuvatris Therapeutics, Inc. was delisted on Aug 8, 2025; its insiders filed their last Form 4 on Mar 14, 2024; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q2 2025
- 13F value
- $0
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding PXMD, Q2 2025
No superinvestor reported holding PXMD at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by Kuvatris Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2024 (view filing)7:55 PM ET | Jan 29 | 2 days | Rome ZacharyDirector | SSale | −811 | $0.48 | −$389.28 | −5.1%15.1K after | |
| Jan 31, 2024 (view filing)5:19 PM ET | Jan 29 | 2 days | LaRochelle KarenDirector | SSale | −78 | $0.48 | −$37.44 | −2.7%2.83K after | |
| Jan 31, 2024 (view filing)5:18 PM ET | Jan 29 | 2 days | Coelho John FDirector | SSale | −27 | $0.48 | −$12.96 | −0.6%4.62K after | |
| Jan 31, 2024 (view filing)5:16 PM ET | Jan 29 | 2 days | Weisman Howard J.Chief Executive Officer | SSale | −372 | $0.47 | −$174.84 | −1.0%37.7K after | |
| Nov 29, 2023 (view filing) | Nov 27 | 2 days | Coelho John FDirector | SSale | −12 | $1.03 | −$12.36 | −0.3%4.64K after | 10b5-1 |
| Nov 29, 2023 (view filing) | Nov 27 | 2 days | Weisman Howard J.Chairman and CEO | SSale | −162 | $1.03 | −$166.86 | −0.4%38.0K after | 10b5-1 |
| Nov 29, 2023 (view filing) | Nov 27 | 2 days | Derby Michael10% Owner | SSale | −185 | $1.03 | −$190.55 | −0.7%25.6K after | 10b5-1 |
| Nov 29, 2023 (view filing) | Nov 27 | 2 days | LaRochelle KarenDirector | SSale | −35 | $1.03 | −$36.05 | −1.2%2.91K after | 10b5-1 |
| Nov 29, 2023 (view filing) | Nov 27 | 2 days | Rome ZacharyDirector | SSale | −359 | $1.03 | −$369.77 | −2.2%16.0K after | 10b5-1 |
| Oct 30, 2023 (view filing)4:13 PM ET | Oct 27 | 3 days | Rome ZacharyDirector | SSale | −16.3K | $0.1848 | −$3.01K | −5.6%277.4K after | 10b5-1 |
Top 10 13F holders, Q2 2025
The largest institutional positions in Kuvatris Therapeutics, Inc. at the end of Q2 2025; share changes are against Q1 2025.
No institution reported holding PXMD in 13F filings for Q2 2025.